Tillkännagivande • Jan 22
AcuCort AB (publ) to Report Fiscal Year 2025 Results on Feb 20, 2026 AcuCort AB (publ) announced that they will report fiscal year 2025 results at 12:00 PM, Central European Standard Time on Feb 20, 2026 Reported Earnings • Nov 19
Third quarter 2025 earnings released Third quarter 2025 results: Revenue: kr2.37m (up 36% from 3Q 2024). Net loss: kr5.34m (loss widened 115% from 3Q 2024). Tillkännagivande • Oct 16
AcuCort AB (publ) to Report Q3, 2025 Results on Nov 14, 2025 AcuCort AB (publ) announced that they will report Q3, 2025 results on Nov 14, 2025 Tillkännagivande • Oct 15
AcuCort Appoints Anna Chérouvrier Hansson as Business Development Director AcuCort has appointed Anna Chérouvrier Hansson as its Business Development Director. The appointment is part of AcuCort's continued commercial development and focus on strengthening strategic partnerships to support the launch of Zeqmelit® in additional markets.Anna Chérouvrier Hansson brings more than 15 years of experience in business development, sales and marketing within the life science sector. She has held senior positions in both listed companies and fast-growing SMEs, including SenzaGen and Camurus.At SenzaGen, she played a key role in building and driving the company's business development and commercialisation strategy, establishing a global network of licensees and distributors, and negotiating international agreements. At Camurus, she was instrumental in the launch of the company's first commercial product in supportive cancer care across several international markets. Reported Earnings • Aug 19
Second quarter 2025 earnings released Second quarter 2025 results: Revenue: kr1.34m (up 5.3% from 2Q 2024). Net loss: kr7.57m (loss widened 99% from 2Q 2024). Tillkännagivande • Jul 21
AcuCort AB (publ) to Report Q2, 2025 Results on Aug 19, 2025 AcuCort AB (publ) announced that they will report Q2, 2025 results on Aug 19, 2025 Reported Earnings • Apr 20
Full year 2024 earnings released Full year 2024 results: Revenue: kr7.72m (up 17% from FY 2023). Net loss: kr17.4m (loss widened 27% from FY 2023). Tillkännagivande • Apr 09
AcuCort AB (publ) to Report Q1, 2025 Results on May 08, 2025 AcuCort AB (publ) announced that they will report Q1, 2025 results on May 08, 2025 Tillkännagivande • Mar 20
AcuCort Receives Renewed Marketing Authorisation for Zeqmelit® in Norway AcuCort has received a renewed marketing authorisation for its medicinal product Zeqmelit® from the Norwegian Medical Products Agency (Direktoratet for medisinske produkter), Norway's equivalent of the Swedish Medical Products Agency. The decision grants approval without a time limitation. AcuCort was first granted a marketing authorisation for Zeqmelit® in Norway in 2022. That approval was time-limited, which is standard for new medicines. Following an application for renewal, the Norwegian Medical Products Agency has now granted an extended marketing authorisation for the Norwegian market, this time without a time restriction. Tillkännagivande • Mar 19
AcuCort Receives Renewed Marketing Authorisation for Zeqmelit® in Denmark AcuCort has received a renewed marketing authorisation for its medicinal product Zeqmelit from the Danish Medicines Agency (Laegemiddelstyrelsen), Denmark's equivalent of the Swedish Medical Products Agency. The decision grants approval without a time limitation. AcuCort was first granted a marketing authorisation for Zeqmelit in Denmark in 2022. That approval was time-limited, which is standard for new medicines. Now, following an inspection by the Swedish Medical Products Agency, the Danish Medicines Agency has granted an extended marketing authorisation, this time without a time limitation. Tillkännagivande • Mar 05
AcuCort AB (publ) Receives Renewed Marketing Authorisation from the Swedish Medical Products Agency AcuCort AB (publ) has received renewed marketing authorisation for its medicinal product Zeqmelit® from the Swedish Medical Products Agency. The decision is valid indefinitely. AcuCort applied for and was granted marketing authorization for its medicinal product in 2020. That authorization was valid for a period of five years, which is standard practice for new medicines. As a result, AcuCort applied for an extension, and the Swedish Medical Products Agency has now granted renewed marketing authorisation, effective from 6 October 2025. This time, the authorisation is valid without time limitation. Tillkännagivande • Jan 23
AcuCort AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025 AcuCort AB (publ) announced that they will report fiscal year 2024 results on Feb 21, 2025 New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr26m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 14% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Revenue is less than US$1m (kr7.0m revenue, or US$629k). Market cap is less than US$10m (€6.94m market cap, or US$7.14m). Reported Earnings • Dec 04
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: kr1.74m (up 1.2% from 3Q 2023). Net loss: kr2.48m (loss narrowed 21% from 3Q 2023). New Risk • Nov 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr25m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (281% increase in shares outstanding). Revenue is less than US$1m (kr7.0m revenue, or US$642k). Market cap is less than US$10m (€7.40m market cap, or US$7.83m). Tillkännagivande • Nov 14
All Patients Completed AcuCort's Phase IV Study ZEQ001 AcuCort's Phase IV study, ZEQ001, began in late January 2024. This study enrolled 50 patients, and the last participant has now completed it. The study findings are intended to be published in scientific journals, providing key support for AcuCort's upcoming launch initiatives. A key objective of the study, an open, non-randomised, low-intervention study, is to obtain scientific data from patients who previously used tablets but, in the study, are using Zeqmelit® instead. The study will answer essential questions, such as whether patients feel confident with Zeqmelit®, what the experience of using the medication is like, and whether they carry it with them. The study results will be published in scientific journals, thereby providing crucial support for the launch of Zeqmelit® in selected markets. Tillkännagivande • Oct 24
AcuCort AB (publ) to Report Q3, 2024 Results on Nov 22, 2024 AcuCort AB (publ) announced that they will report Q3, 2024 results on Nov 22, 2024 Tillkännagivande • Sep 03
Acucort AB (Publ) Announces Launch of Zeqmelit®? Initiated - Now Available At Pharmacies AcuCort has previously announced that the market launch of Zeqmelit®? would begin in early September. In line with this plan, Zeqmelit®? is available at Swedish pharmacies starting on September 2nd. The product will soon also be available at pharmacies in Norway and Finland. The launch is proceeding exactly as planned, and have thus achieved yet another important milestone. Physicians can prescribe Zeqmelit®?, and the product is now available at Swedish pharmacies. It will soon also be available at hospitals in Norway and Finland. Tillkännagivande • Jul 25
AcuCort AB (publ) to Report First Half, 2024 Results on Aug 23, 2024 AcuCort AB (publ) announced that they will report first half, 2024 results on Aug 23, 2024 Board Change • Jun 17
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Monica Wallter was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Oct 12
AcuCort AB (publ) to Report Q3, 2023 Results on Nov 10, 2023 AcuCort AB (publ) announced that they will report Q3, 2023 results on Nov 10, 2023 Tillkännagivande • Jul 13
AcuCort AB (publ) to Report Q2, 2023 Results on Aug 11, 2023 AcuCort AB (publ) announced that they will report Q2, 2023 results on Aug 11, 2023 